Company

Ascendis Pharma A/S

Headquarters: Hellerup, Denmark

Employees: 639

CEO: Mr. Jan Moller Mikkelsen

NASDAQ: ASND +0.57%

Market Cap

$7.68 Billion

USD as of Jan. 1, 2024

history Market Cap History

Ascendis Pharma A/S market capitalization over time

Evolution of Ascendis Pharma A/S market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Ascendis Pharma A/S

Detailed Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 àŸ/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Top 1-year algo backtest: +240.10%

$10,000 in February 2023 would now be $34,010 by following it 5 minutes per day at market close.

How much did you gain in the last 12 months?

Stocks & Indices

Ascendis Pharma A/S has the following listings and related stock indices.


Stock: NASDAQ: ASND wb_incandescent

Stock: Bovespa: A1SN34 wb_incandescent

Stock: FSX: A71 wb_incandescent

Details

Headquarters:

Tuborg Boulevard 12

Hellerup, 2900

Denmark

Phone: 45 70 22 22 44